Skip to main content

Table 1 Patient characteristics

From: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma

 

No.

%

Total patients enrolled

29

100

   Treated

27

93

Age, years

  

   Median

49

 

   Range

32–64

 

Male gender

24

83

Zubrod performance status

  

   0

7

24

   1

18

62

   2

4

14

Child-Pugh classification

  

   A

29

100

Hepatitis virus serology

  

   Hepatitis B

19

66

   Hepatitis C

0

0

Prior treatment(s)

  

   Surgery

2

7

   Transarterial chemoembolization

16

55

Pretreatment alpha fetoprotein (AFP)

  

   < 400 ng/mL

8

28

   400–10,000 ng/mL

14

48

   > 10,000 ng/mL

7

24

Pretreatment laboratory data, mean ± SD

  

   Bilirubin, mg/dL

0.97 ± 0.34

 

   Albumin, g/dL

3.17 ± 0.47

 

   Aspartate transaminase, U/L

71 ± 33

 

   Alanine transaminase, U/L

42 ± 11

 

   Platelet, × 103/mL

187.5 ± 54.0

 

Metastatic site(s)

  

   Abdominal lymph node

18

62

   Lung

10

35

   Bone

11

38